This article is more than 5 years old. Information may no longer be current.

Nightstar posts quarterly loss

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Nightstar Therapeutics reported a net loss of $7.6 million, or $0.27 per share, for 2018’s third quarter compared with a net loss of $8.2 million, or $0.38 per share, for the same quarter in 2017.

General and administrative costs increased from $2 million to $3 million primarily due to an increase in personnel-related costs to support research and development activities, according to a press release.

Research and development costs increased from $4 million to $7.8 million for the quarter, mostly related to program-related expenses for NSR-REP1 and NSR-RPGR, the company’s product candidates for choroideremia and X-linked retinitis pigmentosa, respectively.

The company had cash, cash equivalents and marketable securities totaling $100.8 million as of Sept. 30.